CAPSOVISION INC (CV)
Health Care · medical devices / diagnostic imaging · NASDAQ
Developer of panoramic, AI-enabled capsule endoscopy systems for non-invasive gastrointestinal diagnostics.
What CAPSOVISION INC does
CapsoVision is a commercial-stage medical technology company that develops capsule endoscopy solutions for GI tract diagnostic and screening purposes. Its product ecosystem includes the CapsoCam Plus panoramic capsule endoscope, alongside CapsoCloud and CapsoView software for video review and AI-assisted pathology detection. The company is actively developing advanced pipeline products for colon imaging and other GI indications such as pancreatic and esophageal disorders.
Recent developments
Launched AI Highlights internationally in the second quarter of 2026 and expects FDA clearance for the tool by the end of the third quarter of 2026. The company appointed David S. Shields, M.D., to the Board of Directors and entered into a $100 million at-the-market equity offering program. CapsoCam Colon 510(k) submission is targeted for the fourth quarter of 2026.
From CAPSOVISION INC's filing of 2026-08-13.
Themes: gastroenterology diagnostics, AI-assisted diagnostics, capsule endoscopy, cloud-based medical software, non-invasive screening
Fundamentals
- Price$6.62 as of 2026-10-08 close
- Market cap$331M as of 2026-08-12 (share count; price 2026-10-08)
- 1-year return+43.9% 2025-10-08 close $4.60 → 2026-10-08 close $6.62
- P/En/a negative earnings
- Net margin-186.8% FY2025, SEC XBRL
- Gross margin+52.9% FY2025, SEC XBRL
- ROE-190.9% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)+0.3% as of 2026-09-03
- Beta0.89 as of 2026-09-03
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How CV compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CAPSOVISION INC looks technically
CAPSOVISION INC (CV) is trading 2.8% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 33 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It made a new 20-day high about 9 trading days ago. It is 56.9% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 8% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 40% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 2.8% below its 200-day average, the long-term trend line — a long-term downtrend | -2.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $6.38 | $6.38 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.81 | $6.81 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 6.98. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 33 trading days ago — a "death cross", a bearish long-term signal | 33 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend) | 16.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 54.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($5.88 to $6.98) — its "stochastic" reading is 67 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 67.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $15.37 | $15.37 |
|---|---|---|
| From the 52-week high | it is 56.9% below its 52-week high (its highest price of the past year) | -56.9% |
| Above the 52-week low | it is 52.5% above its 52-week low (its lowest price of the past year) | +52.5% |
| Below the 52-week high | it is 56.9% below its highest point of the past year | 56.9% |
| Since a 20-day breakout | it made a new 20-day high about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it is trading within its recent 55-day range, with no fresh breakout up or down | 0 sessions |
| All-time high | its highest closing price on record is $15.37 (set on 2025-12-11) | $15.37 |
| Given back of the 52-week move | over the past year its closes ranged ($4.46 to $14.42), and it has given back well over two thirds of its rise from last year’s low — 78% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.95 to $8.26. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 78.3% |
| From the all-time high | it is 56.9% below its all-time high | -56.9% |
| Nearest price level | it is trading 5.2% above a support level at $6.27 — a price it turned at three times since 2026-05-18, most recently on 2026-08-28. Since 2025-07-02 it has 5 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -5.2% |
| All-time low | its lowest closing price on record is $3.45 (set on 2025-09-08) | $3.45 |
| Above the all-time low | it is 91.9% above its all-time low | +91.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 8% of the past ~6 months), which often precedes a bigger move | 8th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3752 between its high and its low — about 5.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3752 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $5.96 and $6.91 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $5.96 – $6.43 – $6.91 |
| Typical daily range (% of price) | its price moves about 5.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.7% |
| Stretch from the 200-day average | it is trading 0.5 daily ranges below its 200-day average price (2.8% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 40% of its 30-day average | 0.40× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 1.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.1% |
|---|---|---|
| Gap filled | a 3.1% gap up opened on 2026-09-21 has been "filled" 13 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 13 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +1.85% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 3.0 percentage points (the stock gained 4.1% while the market gained 1.0%) | +3.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 4.3 percentage points (the stock gained 8.1% while the market gained 3.8%) | +4.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 18.6 percentage points (the stock lost 1.2% while the market gained 17.5%) | -18.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 28.9 percentage points (the stock gained 43.9% while the market gained 15.0%) | +28.9% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 6.5% of the share price. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $6.47 — a volume-weighted average of daily closes over 183 sessions, not a true tick-by-tick VWAP. | +2.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $6.40 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP. | +3.5% |
Double bottom, bullish — forming · entry $7.17 · 66 sessions in
Price levels it has turned at before
CV last closed at $6.62 on 2026-10-08. Since 2025-07-02 it has turned at 5 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $6.27 | Support | 5.2% below the last close | turned there three times · 2026-05-18 to 2026-08-28 |
| $6.99 | Resistance | 5.5% above the last close | turned there twice · 2026-09-08 to 2026-09-29 |
| $7.12 | Resistance | 7.5% above the last close | turned there twice · 2026-01-16 to 2026-07-22 |
| $5.69 | Support | 14.1% below the last close | turned there four times · 2025-11-13 to 2026-08-27 |
| $7.73 | Resistance | 16.7% above the last close | turned there four times · 2026-05-04 to 2026-07-01 |
| $5.02 | Support | 24.2% below the last close | turned there three times · 2025-10-03 to 2026-03-18 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $6.98.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 2 analysts
- Mean price target$9.50 range $9.00 – $10.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["History of net losses with substantial doubt regarding the company's ability to continue as a going concern.","Significant dependence on a single product (CapsoCam Plus) for current revenue.","Regulatory risks associated with FDA and international clinical trial and clearance processes."]
What changed in the latest 10-Q
AI-assisted comparison of CV's 10-Q filed 2026-08-13 against the prior one filed 2026-05-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing states that as of June 30, 2026, CapsoCam Plus has been used in over 176,000 patients.
- Newer filing states that as of the date of the Quarterly Report, the second arm pivotal study enrollment is complete with 801 patients enrolled.
- Newer filing states that the company currently expects to submit the 510(k) application for the Second-Generation Product in the fourth quarter of 2026.
- Newer filing states that in response to the FDA's feedback, a proposal was submitted to the FDA in April 2026.
- Newer filing states that as further requested by the FDA, the company will conduct further demographic analysis of the study data and expects to submit the analysis to the FDA by the end of August 2026.
- Newer filing states that the company anticipates obtaining FDA clearance by the end of the third quarter of 2026 with commercialization planned to begin in the US shortly thereafter.
- Newer filing states that the company made the initial EU submission in January 2026 and submitted the related technical documents in July 2026.
- Newer filing states that by the time of the Quarterly Report, the company has commercialized in the EU.
- Newer filing states that as of the date of the Quarterly Report, three patients have been enrolled in the early pancreatic cancer detection study.
- Newer filing states that the study continues and the company is working on expanding the number of clinical sites participating in the study.
- Newer filing states that as of June 30, 2026, the company had an accumulated deficit of $170.2 million.
- Newer filing includes the sentence: 'Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world.'
- Newer filing includes the sentence: 'When used in this Quarterly Report on Form 10-Q, the terms "we," "us," "our" and "the Company" mean CapsoVision.'
- Removed:
- Older filing states that as of March 31, 2026, CapsoCam Plus has been used in over 167,000 patients.
- Older filing states that over 600 patients have been enrolled in the second arm pivotal study.
- Older filing states that the company expects to submit the 510(k) application for the Second-Generation Product in the third quarter of 2026.
- Older filing states that the company received feedback from the FDA in March 2026 and submitted responses to the FDA in April 2026.
- Older filing states that the company will continue engaging with the FDA and expects to obtain FDA clearance by the middle of 2026.
- Older filing states that as of May 11, 2026, the first patient has been enrolled in the early pancreatic cancer detection study.
- Older filing states that as of March 31, 2026, the company had an accumulated deficit of $162.7 million.
- Older filing includes the sentence: 'Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world.'
- Older filing includes the sentence: 'When used in this Quarterly Report on Form 10-Q, the terms "we," "us," "our" and "the Company" mean CapsoVision.'
- Reworded:
- Newer filing changes 'three months ended March 31, 2026' to 'six months ended June 30, 2026' for the period used to describe the largest international shipping destinations.
- Newer filing changes 'over 600 patients have been enrolled' to 'we have completed the enrollment process of the second arm pivotal study with 801 patients enrolled'.
- Newer filing changes 'currently expects' to 'currently expect' in the sentence about submitting the 510(k) application.
- Newer filing changes 'third quarter of 2026' to 'fourth quarter of 2026' for the expected 510(k) submission timing of the Second-Generation Product.
- Newer filing changes the FDA clearance timing expectation from 'middle of 2026' to 'end of the third quarter of 2026'.
- Newer filing adds EU regulatory and commercialization status for the CapsoCam Plus AI technology.
- Newer filing changes 'As of May 11, 2026, the first patient has been enrolled' to 'As of the date of this Quarterly Report three patients have been enrolled' in the pancreatic cancer detection study.
- Newer filing updates the accumulated deficit from $162.7 million as of March 31, 2026 to $170.2 million as of June 30, 2026.
- Notes:
- The newer filing text is truncated at 'As of June 30, 2026, we had an accumulated deficit of $170.2 million. To date, we have funded our operations primarily through proceeds from the sale of shares of our convertible', so text after that point could not be compared.
- The older filing text is truncated at 'Key Factors Affecting Our Results of Operations', so text after that point could not be compared.
Risk Factors
- Reworded:
- In the going concern summary bullet, the newer filing (filed 2026-08-13) references 'our unaudited financial statements for the six months ended June 30, 2026', while the older filing (filed 2026-05-14) references 'our unaudited financial statements for the three months ended March 31, 2026'.
- In the first Business and Industry Risk Factor paragraph, the newer filing (filed 2026-08-13) states net losses for 'the six months ended June 30, 2026 and June 30, 2025' of '$14.5 million and $10.0 million', while the older filing (filed 2026-05-14) states net losses for 'the three months ended March 31, 2026 and March 31, 2025' of '$7.0 million and $5.4 million'.
- In the first Business and Industry Risk Factor paragraph, the newer filing (filed 2026-08-13) states an accumulated deficit of '$170.2 million' as of 'June 30, 2026', while the older filing (filed 2026-05-14) states an accumulated deficit of '$162.7 million' as of 'March 31, 2026'.
- In the last sentence of the first Business and Industry Risk Factor paragraph, the newer filing (filed 2026-08-13) refers to 'our unaudited financial statements for the six months ended June 30, 2026', while the older filing (filed 2026-05-14) refers to 'our unaudited financial statements for the three months ended March 31, 2026'. The newer filing text is truncated mid-sentence at the end of the excerpt.
- Notes:
- The newer filing excerpt is truncated mid-sentence at the end, so changes occurring after that point cannot be assessed.
- Page number differences (newer page 42 vs. older page 39; newer page 43 vs. older page 40) reflect layout pagination, not substantive text changes.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
5 open-market purchases and 0 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-044 buys ($20M) · 0 sells — 2 buying insiders
- Last 90 days · read to 2026-10-045 buys ($20M) · 0 sells — 2 buying insiders
- Last 180 days · read to 2026-10-047 buys ($21M) · 1 sell ($8587) — 2 buying, 1 selling insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-18. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CV's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding CV as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 2,310,529
- Reported value $17,513,810
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CV's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CV had 1,899,065 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CV had 3.79% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.67 days to cover at the same settlement.
- Reported short interest (shares) 1,899,065
- Short interest (% of shares outstanding) 3.79%
- Prior settlement (shares) 1,880,577
- Reported change 0.98%
- Days to cover (reported) 11.67
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Medtronic (MDT)
- Olympus (OCPNY)
- Fujifilm Holdings (FUJIY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CV vs…
Frequently asked questions
What does CAPSOVISION INC (CV) do?
CapsoVision is a commercial-stage medical technology company that develops capsule endoscopy solutions for GI tract diagnostic and screening purposes. Its product ecosystem includes the CapsoCam Plus panoramic capsule endoscope, alongside CapsoCloud and CapsoView software for video review and AI-assisted pathology detection. The company is actively developing advanced pipeline products for colon imaging and other GI indications such as pancreatic and esophageal disorders.
What sector is CAPSOVISION INC (CV) in?
CAPSOVISION INC (CV) is classified in the Health Care sector. Its industry is medical devices / diagnostic imaging. It trades on NASDAQ.
Who are CAPSOVISION INC's (CV) competitors?
Notable peers of CAPSOVISION INC (CV) include Medtronic, Olympus and Fujifilm Holdings. This peer set is informational only — not financial advice.
Is CAPSOVISION INC (CV) overbought or oversold right now?
CAPSOVISION INC (CV) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CV come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.